Envisia Therapeutics Announces Panel Presentation At Upcoming Citi's 11th Annual Biotech Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 1, 2016 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that Dr. Benjamin Yerxa will participate in a panel titled "Emerging Innovators – An Introduction to Private Biotech Companies" at Citi's 11th Annual Biotech Conference in Boston, MA on Thursday, September 8, 2016.

Event:   Citi's 11th Annual Biotech Conference, Boston, MA
Panel:   Emerging Innovators – An Introduction to Private Biotech Companies  
Date:    Thursday, September 8, 2016
Time:    9:00 am ET

ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

SOURCE Envisia Therapeutics

Related Links

http://www.envisiatherapeutics.com